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Abstract
Aim Heart failure (HF) incidence increases markedly with age. We examined age-associated longitudinal change in cardiac
structure and function, and their prediction by age and cardiovascular disease (CVD) risk factors, in a community-based cohort
aged ≥60 years at increased CVD risk but without HF.
Methods and results CVD risk factors were recorded in 3065 participants who underwent a baseline echocardiographic ex-
amination, of whom 2358 attended a follow-up examination 3.8 [median, inter-quartile range (IQR) 3.5, 4.2] years later. Me-
dian age was 71 (IQR 67, 76) years and 55% of participants were male. Age was associated with longitudinal increase in left
ventricular (LV) mass index (LVMI); decrease in LV volumes; increase in LV ejection fraction; decrease in mitral annular sys-
tolic velocity; decrease in diastolic function (decreased mitral early diastolic annular velocity (e′); and increase in left atrial
volume index, mitral peak early diastolic flow velocity (E)/e′ ratio, and tricuspid regurgitant velocity (TRVmax) in men and
women, except for TRVmax in men). In multivariable analysis, longitudinal increase in LVMI was explained by CVD risk factors
alone, whereas age, together with CVD risk factors, independently predicted longitudinal change in all other echocardio-
graphic parameters. CVD risk factors were differentially associated with longitudinal change in different echocardiographic
parameters.
Conclusions Whereas the increase in LVMI with age was explained by CVD risk factors alone, age, together with risk factors,
independently predicted longitudinal change in all other echocardiographic parameters, providing evidence for age-specific
mechanisms of change in cardiac structure and function as people age. Age-associated change in LVMI, LV volumes, and dia-
stolic function resembled what might be expected for the evolution of HF with preserved ejection fraction. Given the differ-
ential association of different CVD risk factors with longitudinal change in different echocardiographic parameters, therapies
aimed at attenuation of age-associated change in cardiac structure and function, and HF evolution, will likely need to address
multiple CVD risk factors.
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Introduction
Heart failure (HF) incidence and prevalence increase strikingly
with age, with a lifetime risk of 20–46%,1 making it the
quintessential cardiovascular syndrome of aging that results
from age-associated changes in cardiovascular structure and
function and cardiovascular disease (CVD) risk factors.2 Key
to the prevention of age-associated changes in cardiac
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structure and function that lead to HF is an understanding of
the relative contribution of age and CVD risk factors to these
changes.
Most information about the association of age with
cardiac structure and function comes from cross-sectional
studies,3–15 and fewer studies examined longitudinal change
in cardiac structure and function.16–21 Both cross-sectional
and longitudinal studies report decrease in left ventricular
(LV) end-diastolic volume index (LVEDVI), left ventricular
end-systolic volume index (LVESVI), and left ventricular stroke
volume index (LVSVI)5,6,9–11,20 and increase in LV mass (LVM)/
end-diastolic volume (EDV) ratio with age.6,15,20 Additionally,
cross-sectional studies report decrease in mitral annular sys-
tolic velocity (S′) and mitral early diastolic annular velocity
(e′) and increase in mitral peak early diastolic flow velocity
(E)/e′ ratio and pulmonary artery systolic pressures [derived
from tricuspid regurgitant velocity (TRVmax)] with
age.5,7,12,14,15 There are, however, discrepancies between re-
ports of age-associated change in cardiac structure and func-
tion. LVM or LVM index (LVMI) is reported to increase with
age in some studies,5,9,10,15,16,18 but not in others,3,4,6 or to
increase in men and decrease in women.20 LV ejection frac-
tion (LVEF) is reported to increase,6,9,10,17 to not change,15
or to decrease with age.21 Left atrial volume (LAV) and LAV in-
dex (LAVI) are reported either to not change5,10 or to increase
with age.8,13
In addition to uncertainty about age-associated change in
cardiac structure and function, there is limited information
about the contribution of age and CVD risk factors to these
changes.15,16,18–20,22 To define the effect of age on cardiac
structure and function, and the relationship of CVD risk fac-
tors with age-associated change in cardiac structure and func-
tion, we performed serial echocardiographic examinations in
the participants of the SCReening Evaluation of the Evolution
of New HF (SCREEN-HF) study,23–26 a prospective
community-based cohort study of men and women ≥60 years
of age without HF but with risk factors for HF.
Methods
Study population
The SCREEN-HF study is a community-based evaluation of the
use of plasma amino-terminal-pro-B-type natriuretic peptide
(NT-proBNP) to identify individuals with cardiac dysfunction
(as assessed by echocardiography) and increased risk of HF
and other cardiovascular events.23–26 A flow chart for partic-
ipant recruitment and follow-up is shown in Figure S1. In
summary, 44 000 members of private health fund Bupa and
residents of Melbourne or Shepparton, Victoria, Australia,
were invited to participate. Inclusion criteria were
age ≥ 60 years with one or more of self-reported treatment
for hypertension or diabetes for ≥2 years, myocardial infarc-
tion (MI), or other ischaemic heart disease (IHD) or valvular
heart disease, irregular or rapid heart rhythm, cerebrovascu-
lar disease, or renal impairment. We excluded individuals
with previously diagnosed HF and those with
well-recognized HF risk such as previous valve surgery or doc-
umented valve abnormality graded > mild, LVEF < 50%, or
other known cardiac abnormality on previous echocardiogra-
phy or other cardiac imaging. We did not exclude individuals
with previously reported diastolic dysfunction because it was
infrequently reported on, and because of the lack of consen-
sus regarding classification of diastolic dysfunction in the
years before recruitment, which commenced in May 2007
and was completed in January 2010. Documentation of previ-
ous cardiac imaging was requested from hospitals and from
the participant’s primary care provider, physician, and cardi-
ologist. However, for this community-based cohort, most par-
ticipants had not had cardiac imaging before enrolment.
Of the 4054 individuals enrolled at the baseline visit (Visit
1), 3847 met the inclusion and exclusion criteria and were in-
vited to attend for echocardiographic examination (Visit 2).
Excluding participants who developed HF before Visit 2, echo-
cardiography was performed in 3190 participants at a median
of 1.3 [inter-quartile range (IQR) 0.5, 1.9] years after enrol-
ment. We previously reported comparison of participants
who came for the baseline echocardiographic examination
and those who did not.25 Participants were invited to return
for a second echocardiographic examination (Visit 3) at a me-
dian of 3.8 (IQR 3.5, 4.2) years after the baseline echocardio-
graphic examination.25 Participants who were diagnosed with
HF and/or MI between Visit 2 and Visit 3 (n = 125) were ex-
cluded, and the number of participants with baseline echo-
cardiography for this study was 3065, of which 2358
returned for a second echocardiographic examination. The
SCREEN-HF study was approved by the Alfred Human Re-
search Ethics Committee and conformed to the ethical stan-
dards of the Declaration of Helsinki, and written informed
consent was obtained from all participants. The study was
registered at ClinicalTrials.gov NCT00400257, NCT00604006,
and NCT01581827.
Clinical assessment
The baseline visit was conducted by a study research nurse
who consented, interviewed, and examined the participant.
Height, weight, waist circumference, and blood pressure
(BP) were measured at interview, and age, sex, and past med-
ical history were recorded. Self-reported details of lifestyle
factors included exercise, smoking history, and alcohol intake.
Physical activity was assessed using the New York Heart Asso-
ciation questionnaire,27 and physical inactivity refers to par-
ticipants who did not walk for, on average, ≥30 min/day
and/or participate in, on average, ≥10 min/day of more
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vigorous exercise, including housework. Alcohol > 2
drinks/day refers to consumption of more than two standard
drinks on any day.28
Participants brought details of their medications to the
baseline study visit, which were recorded. A non-fasting
blood sample was taken for measurement of electrolytes,
creatinine, urea, glucose, and NT-proBNP and for full blood
examination. Details of clinical history and medication were
updated; measurement of height, weight, waist circumfer-
ence, and BP was repeated at Visit 2; and a non-fasting blood
sample was taken for measurement of HbA1c, serum lipids,
and NT-proBNP.
BP was measured with an automatic BP monitor (A&D
Medical, Kensington, Victoria), as previously described.23
Body mass index (BMI) was calculated as the ratio of weight
to height squared (kg/m2). Estimated glomerular filtration
rate (eGFR) was calculated using the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation.29 Serum
NT-proBNP was measured by electrochemiluminescence im-
munoassay using an Elecsys instrument (Roche Diagnostics,
Basel, Switzerland) with a lower limit of detection of
0.6 pmol/L (to convert pmol/L to pg/mL, multiply by 8.457).
HbA1c was measured by high-performance liquid chromatog-
raphy using an Akray Adams HA-8160 HbA1c analyser.
Whereas data for eGFR, haemoglobin, white cell and platelet
count were from Visit 1, NT-proBNP, HbA1c, and lipid mea-
surements were from Visit 2. The haemoglobin, white cell,
and platelet count cut points were the lower (for
haemoglobin and platelet count) and upper (for white cell
count) limits of the normal range for the laboratory (Table 1).
Echocardiography
Cardiac structure and function were assessed using transtho-
racic echocardiography with either a Vivid 7 (n = 2834) or
Vivid i (n = 231) instrument (GE Healthcare, Chicago, Illinois,
USA).25 Echocardiography was performed according to Amer-
ican Society of Echocardiography and European Association
of Cardiovascular Imaging guidelines.11,30–32 Data were
stored in raw data format and analysed offline by two expe-
rienced cardiologists. Inter-observer intraclass correlation co-
efficients (ICCs) for M-mode measurements were >0.78 for
wall thickness, >0.88 for LA diameter and >0.9 for other
M-mode measurements, ≥0.87 for two-dimensional (2D)
measurements, >0.85 for standard Doppler measurements
except pulmonary vein (PV) A wave velocity, and >0.92 for
tissue Doppler measurements. Intra-observer ICCs were gen-
erally higher than for inter-observer ICCs.
LV dimensions were estimated using the 2D-guided M-
mode approach.11 LVM was calculated using the linear
method11 and indexed to body surface area. LVEF was calcu-
lated using the modified Simpson’s biplane method. Where
endocardial definition was poor in both four-chamber and
two-chamber views, the LVEF was visually estimated and LV
volumes were not calculated.
LAV was calculated using the biplane method of disks from
LA areas measured in the apical four-chamber and
two-chamber views in the frame prior to mitral valve
opening.11 LV inflow was obtained using pulsed wave Doppler
in the apical four-chamber view and E velocity measured; me-
dial and lateral mitral S′ and e′ velocities were measured from
pulsed tissue Doppler imaging, and the ratio of E velocity to
the average of medial and lateral e′ (E/e′ ratio) was obtained.
Peak TRVmax was measured by continuous-wave Doppler.
32
Statistical analysis
Data are reported as median (IQR) or numbers (percent) un-
less otherwise specified. Baseline values for each echocardio-
graphic parameter were adjusted for regression to the mean,
separately for men and women, as described by James.33
Data were analysed using linear regression when the base-
line echocardiographic parameter was the outcome variable
and using mixed-effects models when the outcome was the
covariate effect on the longitudinal change (gradient) in the
outcome variable. All linear regression models included age
and gender as covariates. Mixed-effects model analysis of
longitudinal change in echocardiographic parameters was
performed as described by Eng et al.20 The time covariate
was equal to 0 for the baseline echocardiographic parame-
ters; for the follow-up parameters, the time variable was
equal to the elapsed time between baseline and follow-up ex-
aminations. Time was treated as a random effect, with uncor-
related random intercept and slope by subject in the
mixed-effects model; risk factors were considered fixed ef-
fects that were constant between baseline and follow-up
time points.34 Data were analysed with two multivariable
mixed-effects regression models. For Model 1, age at base-
line, follow-up time, and gender were covariates, with inter-
action terms between gender and the other two covariates,
and the interaction term between all three covariates repre-
sented how longitudinal change varied with age. For Model 2,
multivariable models for longitudinal change included age at
baseline, gender, and the respective baseline echocardio-
graphic parameter value, with interaction terms between
each covariate and follow-up time that represented the co-
variate effect on the longitudinal change of the outcome var-
iable (gradient in echocardiographic parameter value).20
Model fit to the data were assessed by inspecting plots of re-
siduals against predicted values to look for non-random pat-
terns that may indicate non-linearity or heteroscedasticity.
Multivariable models of CVD risk factors were constructed
using stepwise forward selection. Excluded variables were
reassessed for entry into the model when a new variable
was retained by the model, and competing models were
compared using Akaike’s information criteria.
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Table 1 Characteristics of SCREEN-HF participants at baseline echocardiographic study
Characteristic n = 3065
Age (years) 71 (67, 76)
Male (%) 1673 (55%)
Systolic blood pressure (mmHg) 139 (128, 150)
Diastolic blood pressure (mmHg) 76 (69, 83)
Pulse pressure (mmHg) 62 (54, 72)
Body mass index (kg/m2) 28 (26, 31)
Body surface area (m2) 1.9 (1.8, 2.1)
Waist circumference (cm) 98 (90, 106)
Cardiovascular disease risk factors
Hypertension 2792 (91%)
Diabetes 529 (17%)
Obesity 1066 (35%)
Previous myocardial infarction 312 (10%)
Total ischaemic heart disease 694 (23%)
Previous stroke or transient ischaemic attack 347 (11%)
Peripheral vascular disease 110 (3.6%)
Cardiovascular disease 987 (32%)
Atrial fibrillation 359 (12%)
Pacemaker 69 (2.3%)
Obstructive sleep apnoea 217 (7.1%)
Current or former smoker 1487 (49%)
Current smoker 93 (3.0%)
Alcohol >2 drinks/day 614 (20%)
Physical inactivity 2011 (66%)
Medication use
Beta-blocker 702 (23%)
ACE inhibitor 948 (31%)
ARB 1507 (49%)
ACE inhibitor and/or ARB 2359 (77%)
Calcium channel blocker 930 (30%)
Statin therapy 1687 (55%)
Thiazide diuretic 1003 (33%)
Loop diuretic 108 (3.5%)
Mineralocorticoid antagonist 23 (0.8%)
Digoxin therapy 84 (2.7%)
Aspirin therapy 1360 (44%)
Clopidogrel therapy 207 (6.8%)
Warfarin therapy 180 (5.9%)
NSAID therapy 318 (10.4%)
Insulin therapy 91 (3.0%)
Oral anti-diabetic medication 372 (12%)
Nitrate therapy 148 (4.8%)
Biochemistry and haematology
NT-proBNP (pmol/L), n = 2941 12 (6, 25)
Total cholesterol (mmol/L), n = 2939 4.8 (4.1, 5.5)
Triglycerides (mmol/L), n = 2939 1.5 (1.1, 2.1)
High-density lipoprotein cholesterol, n = 2939 1.2 (1.0, 1.5)
eGFR (mL/min/1.73 m2), n = 3065 76 (64, 86)
eGFR <60 mL/min/1.73 m2 613 (20%)
HbA1c (%), n = 2797 5.6 (5.4, 5.9)
Haemoglobin (g/dL), n = 3064 14.0 (13.2, 14.9)
Low haemoglobin (<13 g/L, male; <12 g/L, female) 291 (9.5%)
White cell count (×109/L), n = 3064 7.0 (6.0, 8.2)
High white cell count (>11 × 109/L) 70 (2.3%)
Platelets (×109/L), 3058 228 (194, 266)
Low platelet count (<150 × 109/L) 123 (4.0%)
Data shown as median (inter-quartile range) or n (%). Alcohol >2 drinks/day refers to consumption of more than two standard drinks on
any day. Total ischaemic heart disease refers to myocardial infarction, coronary revascularization, coronary artery disease detected on cor-
onary angiography, and angina. Cardiovascular disease refers to total ischaemic heart, cerebrovascular, and peripheral vascular disease.
Data for cardiovascular disease, diabetes, obstructive sleep apnoea, smoking, alcohol intake, drug therapy, and physical activity were from
self-report. Physical inactivity refers to failure to walk ≥ 30 min/day and/or participate in, on average, ≥10 min/day of more vigorous exer-
cise, including housework.
ACE, angiotensin-converting enzyme; ARB, angiotensin II type 1 receptor blocker; eGFR, estimated glomerular filtration rate calculated
using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation29; NT-proBNP, amino-terminal pro-B-type natriuretic
peptide; NSAID, non-steroidal anti-inflammatory drug.
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The choice of risk factors, including haemoglobin level,
white cell, and platelet count, was based in part on predictors
of HF previously identified in the SCREEN-HF cohort.24 Al-
though frequently a statistically significant predictor of the
outcome variable in univariate analysis, NT-proBNP was not
included in multivariable models because it was considered
to be primarily a response to change in cardiac structure
and function, rather than a potential cause. Data were
analysed using Statview version 5.0.1 (SAS Institute, Vary,
NC, USA) and R version 3.6.0.
Results
Subject characteristics
Baseline characteristics (Table 1) corresponded to the inclu-
sion and exclusion criteria. Median age of the 3065 partici-
pants was 71 (IQR 67, 76) years, 55% were male, and 91%
were Bupa members.
Age-associated change in cardiac structure and
function
Because this was a community-based study, varying image
quality did not allow measurement of all echocardiographic
parameters in all participants, with TRVmax measured in 45%
of participants at the baseline examination and 61% of partic-
ipants at the follow-up examination (Table 2).
Age was associated with longitudinal increase in LVMI,
LVM/EDV ratio, and relative wall thickness (RWT), decrease
in LV chamber volumes (LVEDVI, LVESVI, and LVSVI), increase
in LVEF, decrease in mitral S′, and decrease in diastolic func-
tion (decrease in mitral e′ and increase in LAVI, mitral E/e′ ra-
tio, and TRVmax) in men and women, except for TRVmax in men
(Table 3, Figures 1 and 2). Cross-sectional changes in LVMI,
LVM/EDV ratio, RWT, LVEDVI, and LVSVI were in the same di-
rection, but of lesser magnitude than longitudinal changes in
these parameters (Table 3). There was no cross-sectional
change in LVESVI and a cross-sectional decrease in LVEF, in
contrast to longitudinal increase in LVEF. Cross-sectional
changes in mitral S′, LAVI, mitral e′, and E/e′ ratio were in
the same direction, but of lesser magnitude than longitudinal
change in these parameters, whereas a cross-sectional
change in TRVmax was in the same direction and of similar
magnitude to its longitudinal change.
The interaction between longitudinal and cross-sectional
changes allowed estimation of how longitudinal change var-
ied with age (Table 3). Longitudinal increase in LVMI and
RWT increased with age in women, and longitudinal increase
in LVM/EDV ratio increased with age in both men and
women. Longitudinal decreases in LVEDVI and LVSVI did not
change with age. However, longitudinal decrease in LVESVI
and increase in LVEF were of greater magnitude in older
women, whereas longitudinal decrease in S′ was of greater
magnitude in older men. The longitudinal decrease in e′ and
longitudinal increases in LAVI, E/e′ ratio, and TRVmax were all
of greater magnitude as age increased in both men and
women.
Multivariable predictors of baseline
echocardiographic parameters
Univariate predictors of baseline echocardiographic parame-
ters are shown in Tables S1–S12; multivariable predictors
are shown in Tables S13–S24 and summarized in Table S25.
Abridged data are presented in Table 4 for multivariable pre-
dictors of baseline LVMI, LVEDVI, S′, e′, and E/e′ ratio. Given
that the predominant cross-sectional and longitudinal
changes in these five parameters were increase in LVMI; de-
crease in LVEDVI, S′, and e′; and increase in E/e′ ratio, Figure
3 summarizes multivariable predictors of higher baseline
LVMI; lower baseline LVEDVI, S′, and e′; and higher baseline
E/e′ ratio.
Prediction of baseline echocardiographic parameters by
age in multivariable analysis with CVD risk factors (Tables 4,
S13–S24) was in agreement with the cross-sectional change
per decade of baseline age for men and women, separately,
without adjustment for CVD risk factors (Table 3). Age was
a predictor of all baseline echocardiographic parameters ex-
cept for LVESVI, predicting higher LVMI, LVM/EDV ratio, and
RWT; lower LVEDVI, LVSVI, LVEF, and S′; and impaired dia-
stolic function (lower e′ and higher LAVI, E/e′ ratio, and TR-
Vmax) in multivariable analysis (Tables 4, S13–S25). Similarly,
prediction of baseline echocardiographic parameters by male
gender in multivariable analysis with CVD risk factors (Tables
4, S13–S24) was in agreement with the effect of gender with-
out adjustment for CVD risk factors (Table 3). Male gender
predicted higher baseline LVMI and LAVI, whereas female
gender predicted higher LVM/EDV ratio, LVEF, and E/e′ ratio
and lower LV volumes, S′, and e′ (Tables 4, S13–S25).
CVD risk factors were differentially associated with base-
line echocardiographic parameters in multivariable analysis
(Tables 4, S13–S25). A history of hypertension, but not sys-
tolic BP (SBP) measured at the baseline echocardiographic
visit, predicted higher LVMI and LVM/EDV ratio and lower e
′, whereas SBP predicted higher LVEF, LAVI, and TRVmax and
lower S′. Diastolic BP (DBP) predicted higher RWT and E/e′ ra-
tio and lower LVSVI, LVEF, S′, and e′. Pulse pressure (PP) pre-
dicted higher LVMI, LVEDVI, LVSVI, e′, E/e′ ratio, and TRVmax.
Antihypertensive therapies differed in their prediction of
baseline echocardiographic parameters. Both calcium chan-
nel blocker (CCB) and angiotensin-converting enzyme inhibi-
tor (ACEI) therapies predicted higher LAVI. CCB therapy, but
not ACEI and/or ARB therapies, predicted higher LVMI,
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LVEDVI, LVSVI, E/e′ ratio, and TRVmax, whereas ACEI and/or
ARB therapy predicted higher LVEF.
MI and/or IHD did not predict baseline LVM, although MI
predicted lower RWT and LVEF and higher LVEDVI, LVESVI
and LAVI, and IHD predicted lower S′ in multivariable analysis.
Atrial fibrillation (AF) (or warfarin or digoxin therapy) pre-
dicted higher LVMI, LVM/EDV ratio, RWT, LAVI, e′, and TRVmax
and lower LVEF and S′.
Diabetes (or HbA1c) and/or anti-diabetic therapy did not
predict baseline LVMI, LVEF, S′, or TRVmax but predicted
higher LVM/EDV ratio, RWT, and E/e′ ratio and lower LV vol-
umes, LAVI, and e′ in multivariable analysis. Neither BMI nor
waist circumference predicted baseline LVMI, and they pre-
dicted opposite changes in LVM/EDV ratio; BMI predicted
higher LVM/EDV ratio, consistent with its prediction of lower
LVEDVI, whereas waist circumference predicted lower
LVM/EDV ratio. BMI also predicted higher E/e′ ratio, whereas
waist circumference predicted higher RWT, S′, and TRVmax
and lower LVEF. Consistent with the effects of diabetes (or
HbA1c), serum triglyceride level predicted higher LVM/EDV
ratio and lower LV volumes, LAVI, and e′. Triglyceride level
also predicted higher S′.
Physical inactivity was associated with amplification of
age-associated changes in baseline echocardiographic param-
eters, predicting higher LVM/EDV ratio and E/e′ ratio and
lower LVEDVI, LVSVI, LVEF, and S′ in multivariable analysis.
Multivariable predictors of longitudinal change
(gradient) in echocardiographic parameters
Longitudinal change in echocardiographic parameters repre-
sented the rate of change over time (per decade). Thus, pre-
dictors of longitudinal change within a multivariable model
may predict a positive change in gradient (more rapid in-
crease or less rapid decrease in longitudinal change) or nega-
tive change in gradient (more rapid decrease or less rapid
increase). Univariate predictors of longitudinal change in
echocardiographic parameters are shown in Tables S1–S12;
multivariable predictors are shown in Tables S13–S24 and
summarized in Table S26. Abridged data for multivariable
predictors of longitudinal change in LVMI, LVEDVI, S′, e′, and
E/e′ ratio are presented in Table 5. Multivariable predictors
of the predominant longitudinal change in these five param-
eters—more rapid increase in LVMI; more rapid decrease in
LVEDVI, S′, and e′; and more rapid increase in E/e′ ratio—
are summarized in Figure 4.
The complexity of interaction of CVD risk factors with lon-
gitudinal change in echocardiographic parameters was illus-
trated by the variable effects of gender in multivariable
analysis. LVMI, LVM/EDV ratio, LVEF, E/e′ ratio, and TRVmax
gradients were positive for both men and women, and
women had a more rapid increase than men (Tables 5,
S13–S24, S26, Figures 1, 2, and 4). By contrast, S′ gradient
was negative for men and women, and men had a more rapid
decrease than women (Figures 2 and 4). LVEDVI and e′ gradi-
ents were also negative for men and women, and women had
a more rapid decrease than men (Figures 1, 2, and 4).
In contrast to the varying interaction between longitudinal
and cross-sectional changes per decade when analysed with-
out CVD risk factors (Table 3), age was a predictor of longitu-
dinal change in all echocardiographic parameters except for
LVMI in multivariable analysis with CVD risk factors (Tables
S13–S24, S26, Figure 4). Age predicted more rapid increase
in LVM/EDV ratio, RWT, LVEF, LAVI, E/e′ ratio, and TRVmax,
and more rapid decrease in LVEDVI, LVESVI, LVSVI, S′, and e′.
SBP, together with PP, at the time of the baseline echocar-
diographic examination predicted more rapid increase in
Table 2 Echocardiographic parameters at baseline and follow-up echocardiographic studies
Parameter
Baseline echocardiographic examination (n = 3065) Follow-up echocardiographic examination (n = 2358)
n Median (inter-quartile range) n Median (inter-quartile range)
LVMI (g/m2) 2553 90 (82, 99) 1852 94 (82, 110)
LVM/EDV ratio (g/mL) 1983 2.00 (1.85, 2.18) 1340 2.24 (1.93, 2.61)
RWT 2561 0.36 (0.34, 0.39) 1849 0.43 (0.39, 0.48)
LVEDVI (mL/m2) 2280 45 (41, 51) 1567 42 (37, 48)
LVESVI (mL/m2) 2280 18 (16, 21) 1567 16 (14, 19)
LVSVI (mL/m2) 2280 27 (25, 30) 1567 25 (22, 29)
LVEF (%) 3062 60 (58, 61) 2356 60 (58, 63)
S′ (cm/s) 2801 7.50 (7.02, 8.03) 2286 7.18 (6.31, 8.18)
LAVI (mL/m2) 2925 33 (29, 38) 2349 37 (31, 43)
e′ (cm/s) 2842 7.41 (6.77, 8.04) 2324 6.57 (5.53, 7.64)
E/e′ ratio 2753 9.22 (8.20, 10.49) 2322 10.64 (8.67, 12.97)
TRVmax (m/s) 1390 2.42 (2.34, 2.51) 1445 2.44 (2.27, 2.61)
Data shown as median (inter-quartile range).
BSA, body surface area; e′, average early diastolic mitral annular tissue Doppler velocity; E/e′ ratio, peak early diastolic mitral flow velocity/e′
ratio; LAVI, left atrial volume indexed to BSA; LVEDVI, left ventricular end-diastolic volume indexed to BSA; LVEF, left ventricular ejection
fraction; LVESVI, left ventricular end-systolic volume indexed to BSA; LVM/EDV ratio, left ventricular mass/end-diastolic volume ratio; LVMI,
left ventricular mass (linear method) indexed to BSA; LVSVI, left ventricular stroke volume indexed to BSA; RWT, relative wall thickness; S′,
average systolic mitral annular tissue Doppler velocity; TRVmax, peak tricuspid regurgitant flow velocity.
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LVMI; SBP also predicted less rapid decrease in LVEDVI and
LVESVI and more rapid increase in LVEF and LAVI in multivar-
iable analysis. Hypertension predicted more rapid increase in
LVM/EDV ratio, RWT, and LAVI. DBP predicted more rapid de-
crease in LVSVI, less rapid increase in LVEF, less rapid de-
crease in S′, and less rapid increase in E/e′ ratio. PP
predicted less rapid decrease in LVSVI, less rapid increase in
LVEF, less rapid decrease in e′, and more rapid increase in
E/e′ ratio and TRVmax. Both CCB and ACEI and/or ARB thera-
pies predicted less rapid decrease in LVEDVI and more rapid
longitudinal increase in E/e′ ratio. CCB, but not ACEI and/or
ARB therapies, predicted more rapid increase in LVMI, LAVI,
and TRVmax and less rapid decrease in S′. Whereas ACEI
therapy predicted more rapid decrease in LVSVI, CCB therapy
predicted a less rapid decrease.
A history of MI before the baseline echocardiographic ex-
amination predicted more rapid increase in LVMI, LVM/EDV
ratio, and LAVI; less rapid decrease in LVEDVI and LVESVI;
and less rapid increase in LVEF in multivariable analysis. A his-
tory of AF (or warfarin or digoxin therapy) before the baseline
echocardiographic examination predicted more rapid in-
crease in LVMI, LVM/EDV ratio, LAVI, and TRVmax; more rapid
decrease in LVEDVI, LVSVI, and S′; less rapid decrease in
LVESVI and e′; and less rapid increase in LVEF.
Although HbA1c predicted more rapid longitudinal in-
crease in LVMI in univariate analysis (Table S1), neither
Figure 1 Age-related longitudinal and cross-sectional changes in (A) left ventricular mass index (LVMI), (B) left ventricular mass/end-diastolic volume
(LVM/EDV) ratio, (C) relative wall thickness (RWT), (D) left ventricular end-diastolic volume index (LVEDVI), (E) left ventricular end-systolic volume index
(LVESVI), and (F) left ventricular stroke volume index (LVSVI) for men (blue) and women (red). Individual line segments represent observed longitudinal
changes for each age group (in 2 year intervals from age 60–61 to ≥84 years), and the trends between successive line segments represent
cross-sectional patterns among the age groups. Numbers per line: LVMI, 15–132 (men) and 15–125 (women); LVM/EDV ratio, 9–90 (men) and 5–86
(women); RWT, 15–131 (men) and 15–125 (women); LVEDVI, 13–113 (men) and 10–96 (women); LVESVI, 13–113 (men) and 10–96 (women); LVSVI,
13–113 (men) and 10–96 (women).
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diabetes, HbA1c, nor anti-diabetic therapy predicted longitu-
dinal change in LVMI or LVM/EDV ratio in multivariable anal-
ysis (Tables 5, S13, S14, S26, Figure 4). Both HbA1c and
anti-diabetic therapy predicted more rapid increase in E/e′ ra-
tio (Figure 4). Whereas diabetes predicted less rapid increase
in RWT, anti-diabetic therapy predicted more rapid increase
in RWT. HbA1c predicted more rapid decrease in LVSVI,
whereas anti-diabetic therapy predicted more rapid increase
in LVEF and less rapid increase in LAVI. Whereas waist circum-
ference predicted more rapid increase in LVMI, BMI predicted
more rapid increase in LVM/EDV ratio and RWT, and neither
BMI nor waist circumference predicted a change in LV vol-
umes. BMI also predicted less rapid increase in LVEF, more
rapid increase in LAVI and E/e′ ratio, and less rapid increase
in TRVmax, whereas waist circumference predicted less rapid
decrease in S′ and more rapid increase in TRVmax. Triglyceride
level predicted more rapid increase in LVM/EDV ratio, more
rapid decrease in LVESVI, and less rapid decrease in e′,
whereas high-density lipoprotein cholesterol predicted less
rapid increase in LVMI and LVM/EDV ratio.
Physical inactivity predicted less rapid decrease in LVEDVI.
Obstructive sleep apnoea predicted more rapid increase in
Figure 2 Age-related longitudinal and cross-sectional changes, and multivariable predictors of longitudinal change in (A) left ventricular ejection frac-
tion (LVEF), (B) average systolic mitral annular tissue Doppler velocity (S′), (C) left atrial volume index (LAVI), (D) average early diastolic mitral annular
tissue Doppler velocity (e′), (E) peak early diastolic mitral flow velocity/e′ (E/e′) ratio, and (F) peak tricuspid regurgitant flow velocity (TRVmax) for men
(blue) and women (red). Individual line segments represent observed longitudinal changes for each age group (in 2 year intervals from age 60–61 to
≥84 years), and the trends between successive line segments represent cross-sectional patterns among the age groups. Numbers per line: LVEF, 24–
182 (men) and 26–150 (women); S′, 20–165 (men) and 23–138 (women); LAVI, 22–180 (men) and 24–149 (women); e′, 23–173 (men) and 25–139
(women); E/e′ ratio, 22–166 (men) and 24–135 (women); TRVmax, 6–54 (men) and 12–69 (women).
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LVM/EDV ratio and more rapid decrease in LVEDVI and
LVESVI. Renal dysfunction (eGFR < 60 mL/1.73 m2) was asso-
ciated with amplification of age-associated longitudinal
change in echocardiographic parameters, predicting more
rapid increase in LVM/EDV ratio and RWT and more rapid de-
crease in LVEDVI, LVESVI, and S′.
Differential prediction of baseline
echocardiographic parameters and longitudinal
change by cardiovascular disease risk factors in
multivariable analysis
CVD risk factor prediction of a baseline echocardiographic pa-
rameter was often discordant with their prediction of longitu-
dinal change in that parameter in multivariable analysis
(Tables 4, 5, S13–S26, Figures 3 and 4). Male gender pre-
dicted higher baseline LVMI, whereas female gender pre-
dicted more rapid increase in LVMI (Figures 3 and 4).
Moreover, female gender predicted lower baseline S′,
whereas male gender predicted more rapid decrease in S′.
Hypertension predicted higher baseline LVMI, whereas SBP
and PP predicted more rapid increase in LVMI. AF predicted
higher baseline LVMI, whereas warfarin therapy (but not AF
in either univariate or multivariable analysis) predicted more
rapid increase in LVMI. However, AF predicted both higher
baseline LVM/EDV ratio and more rapid increase in
LVM/EDV ratio. AF (or warfarin or digoxin therapy) did not
predict baseline LV volumes, although it predicted a more
rapid decrease in LVEDVI and LVSVI. Neither MI nor IHD pre-
dicted baseline LVMI, but a history of MI before the baseline
echocardiographic examination predicted more rapid in-
crease in LVMI and LVM/EDV ratio. BMI predicted lower
baseline LVEDVI but did not predict longitudinal change in
LVEDVI. Neither reduced eGFR nor obstructive sleep apnoea
predicted baseline LV volumes, but both predicted more
rapid decrease in LVEDVI and LVESVI. In contrast to its predic-
tion of lower baseline LVEDVI, physical inactivity predicted
less rapid decrease in LVEDVI in both univariate and multivar-
iable analyses (Tables S4, S16).
Discussion
Age-associated longitudinal change in cardiac structure and
function included increase in LVMI, decrease in LV volumes,
increase in LVEF, decrease in S′, and deterioration in diastolic
function. Whereas CVD risk factors alone explained the in-
crease in LVMI, age, together with risk factors, independently
predicted longitudinal change in all other echocardiographic
parameters, providing evidence for age-specific mechanisms
of change in cardiac structure and function as people age.
CVD risk factors were differentially associated with longitudi-
nal change in different echocardiographic parameters.
Figure 3 Diagrammatic summary of multivariable predictors of increase in baseline ventricular mass indexed to body surface area (LVMI), decrease in
baseline left ventricular end-diastolic volume indexed to body surface area (LVEDVI), decrease in baseline peak systolic mitral annular velocity (S′), de-
crease in baseline average peak early diastolic mitral annular velocity (e′), and increase in baseline peak early diastolic mitral velocity to average peak
early diastolic mitral annular velocity ratio (E/e′ ratio). AF, atrial fibrillation; BMI, body mass index; CCB, calcium channel blocker; DBP, diastolic blood
pressure; Hb, haemoglobin; HT, hypertension; IHD, ischaemic heart disease; PP, pulse pressure; SBP, systolic blood pressure; TG, triglyceride. Data from
Table 4. Shown in parentheses are univariate predictors associated with the multivariable predictors (from Tables S1, S4, S8, S10, and S11).
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Although LV volumes are usually described as ‘normal’ in HF
with preserved ejection fraction (HFpEF),35 age-associated
decrease in LVEDVI, together with increase in LV wall thick-
ness and its increased stiffness,36 would be accompanied by
an impaired ability of the LV to fill during diastole, such that
a normal or increased LVEF may fail to ensure a cardiac out-
put sufficient to meet metabolic needs. The age-associated
decrease in LV volumes, increase in LVMI, increase in LVEF
and deterioration in diastolic function resemble what might
be expected to occur during the evolution of HFpEF. These
data contribute to understanding of age-associated change
in cardiac structure and function and the relative contribution
of age-specific mechanisms and CVD risk factors to these
changes. Therapies aimed at attenuation of age-associated
change in cardiac structure and function, and HF evolution,
likely need to address multiple risk factors.
Longitudinal changes in echocardiographic parameters
exceeded the cross-sectional change, except for TRVmax, and
prediction of longitudinal change by age and CVD risk factors
differed from their prediction of baseline echocardiographic
parameters. Longitudinal studies are superior to
cross-sectional studies in revealing age-associated change in
cardiac structure and function because cross-sectional analy-
ses are affected by the cohort effect.37 Potential contributors
to the cohort effect in this study included changing smoking
prevalence, better treatment of hypertension and hyperlipid-
aemia, and increasing use of coronary interventions that at-
tenuate MI risk and size that may impact differentially on
individuals of different ages. Individuals with a more extreme
change in cardiac structure and/or function may be less likely
to survive to older ages.
The SCREEN-HF cohort was of similar age to the
Multi-Ethnic Study of Atherosclerosis (MESA) cohort.20 Both
cohorts included participants with CVD risk factors, although
the MESA cohort was free of clinical CVD, whereas the
SCREEN-HF cohort included participants with known MI and
IHD. In agreement with Eng et al.,20 we excluded participants
with HF at baseline and participants who experienced MI or
Figure 4 Diagrammatic summary of multivariable predictors of more rapid increase in left ventricular mass indexed to body surface area (LVMI), more
rapid decrease in left ventricular end-diastolic volume indexed to body surface area (LVEDVI), more rapid decrease in peak systolic mitral annular ve-
locity (S′), more rapid decrease in average peak early diastolic mitral annular velocity (e′), and more rapid increase in peak early diastolic mitral velocity
to average peak early diastolic mitral annular velocity ratio (E/e′ ratio). ACEI, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; BMI, body
mass index; CCB, calcium channel blocker; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDLC, high-density lipoprotein
cholesterol; HT, hypertension; MI, myocardial infarction; MinAntag, mineralocorticoid antagonist; NSAID, non-steroidal anti-inflammatory drug;
OSA, obstructive sleep apnoea; Plat, platelet; PP, pulse pressure; SBP, systolic blood pressure; TG, triglyceride. Data from Table 5. Shown in parenthe-
ses are univariate predictors associated with the multivariable predictors (from Tables S1, S4, S8, S10, and S11).
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HF between the baseline and follow-up echocardiographic ex-
aminations. However, other studies of longitudinal change in
cardiac structure and function included participants with inci-
dent HF.17, 18
Our findings for LVMI in men and LV volumes in men and
women were similar to those reported by Eng et al. in the
MESA cohort, where LVM and LV volumes were measured
by magnetic resonance imaging.20 Whereas Eng et al. re-
ported a longitudinal decrease in LVM in women, we ob-
served an increase in LVMI in both men and women, in
agreement with previous reports.16, 18 Our observation of
longitudinal increase in LVEF was in agreement with Kane
et al.,17 although Cauwenberghs et al. reported LVEF to de-
crease with age.21 We also confirmed previous reports of
age-associated deterioration in diastolic function.17, 19, 21
The aging heart
The age-associated increase in LVMI and deterioration in dia-
stolic function observed in this study were consistent with an
age-associated increase in HF risk, as shown by our demon-
stration that stage B HF and diastolic abnormality at the time
of the baseline echocardiographic examination predicted HF
in this cohort.25 Both cellular and molecular mechanisms
have been proposed to account for the changes in cardiac
structure and function that accompany aging,38 and the asso-
ciation of aging with HF.39 These include increased myocar-
dial stiffness that may result from hypertensive LV
remodelling, inflammation, microvascular dysfunction and
rarefaction, fibrosis, oxidative stress, and cardiomyocyte re-
modelling, and dysfunction.35, 40 We previously reported in
a cross-sectional study that diastolic dysfunction of aging
was independent of myocardial fibrosis, microvascular den-
sity, and cardiomyocyte size but was associated with plasma
advanced glycation end-product levels.41
Clinical implications
In addition to demonstrating age was an independent deter-
minant of longitudinal change in cardiac structure and func-
tion, our data confirm the potential for risk factor
modification to attenuate age-associated change in cardiac
structure and function. Eng et al.20 reported that SBP and
BMI were univariate predictors of more rapid increase in
LVM and that DBP, smoking, BMI, and impaired fasting glu-
cose level were univariate predictors of more rapid decrease
in LVEDV. In agreement with these observations, we found
that SBP and waist circumference predicted more rapid in-
crease in LVMI and that hypertension and BMI predicted
more rapid increase in LVM/EDV ratio and RWT in multivari-
able analysis. HbA1c, BMI, physical inactivity, and triglyceride
level predicted lower baseline LV volumes; and obstructive
sleep apnoea, alcohol intake, digoxin therapy, triglyceride
level, and impaired renal function predicted more rapid de-
crease in LV volumes. In addition to the potential for reduc-
tion in BP, BMI, and waist circumference to attenuate
age-associated increase in LVMI, LVM/EDV ratio, and RWT,
our data indicate that BP reduction, prevention of obesity
and diabetes, promotion of physical activity, prevention
and/or treatment of obstructive sleep apnoea, reduction of
alcohol intake, and prevention or attenuation of
age-associated decline in renal function may also contribute
to the reduction of age-associated decline in LV volumes.
The significance of CVD risk factor-associated longitudinal
change in cardiac structure and function in this study was re-
inforced by our observation that many of the same risk fac-
tors predicted HF in the SCREEN-HF cohort24 and were in
agreement with strategies shown to reduce HF incidence
and improve diastolic function. Antihypertensive therapy re-
duces LVMI and myocardial fibrosis,42–44 improves diastolic
dysfunction,42–45 and prevents HF.46–48 Moreover, weight re-
duction in obesity reduces LVM and improves diastolic
function,49–51 and physical activity increases LVEDV, reduces
LV stiffness,52 and is associated with reduced HF incidence.53,
54
Limitations
Our study had a number of limitations. Participants were
aged ≥60 years, but they represented the age range with in-
creased HF incidence.24 The inclusion criteria with respect to
age and CVD risk factors, together with the SCREEN-HF co-
hort comprising volunteers (possible healthy volunteer bias)
who were predominantly members of a health fund, may
be cause for caution in the generalization of our findings to
the general community. However, the SCREEN-HF cohort
was not that dissimilar to the general Australian population
aged ≥60 years; of Australians aged 65–74 years, 70% have
hypertension,55 17% have diabetes,56 38.2% of men and
32.7% of women are obese,57 5% have AF,58 and 53% have
CVD.59 Our findings are therefore likely to be applicable to
the general Australian community. An advantage of enrolling
participants with known IHD was that we were able to exam-
ine its prediction of age-associated change in cardiac struc-
ture and function.
Our inability to measure every echocardiographic parame-
ter in every participant at both examinations reflected the
practicalities of a community-based study where body habi-
tus, such as increased BMI, may compromise image quality.
A potential bias was that those attending the second exami-
nation may have been healthier than those who failed to
attend.
A strength of our study was the number of CVD risk factors
studied, including medications, although we did not adjust for
change in risk factors during follow-up, apart from age. We
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attempted to control for type 1 error in detection of statisti-
cally significant associations by conducting multivariable anal-
ysis. Some predictors may be missing because of limitations
in data collection, and we do not presume causality. Never-
theless, our data show consistency across risk factors in their
association with related echocardiographic parameters,
thereby increasing confidence in the associations reported.
For many risk factors, their associations with longitudinal
change in echocardiographic parameters were similar to
those we previously reported to predict HF,24 and previous
studies show that modification of many of these risk factors
improves cardiac structure and function and reduces HF
incidence.42–51, 53, 54
Conclusions
In this community-based cohort, age was associated with lon-
gitudinal increase in LVMI, decrease in LV volumes, increase
in LVEF, decrease in S′, and deterioration in diastolic function.
Whereas the increase in LVMI with age was explained by CVD
risk factors alone, age, together with risk factors, indepen-
dently predicted longitudinal change in all other echocardio-
graphic parameters, providing evidence for age-specific
mechanisms of change in cardiac structure and function as
people age. Age-associated change in LV volumes, LVMI,
and diastolic function resembled what might be expected
for the evolution of HFpEF. CVD risk factors were differen-
tially associated with longitudinal change in different echo-
cardiographic parameters, and therapies aimed at
attenuation of age-associated change in cardiac structure
and function, and HF evolution, will likely need to address
multiple risk factors.
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Table S1. Univariate predictors of baseline left ventricular
mass indexed to body surface area (LVMI) and LVMI gradient
(change per decade)
Table S2. Univariate predictors of baseline left ventricular
mass/end-diastolic volume ratio (LVM/EDV ratio) and
LVM/EDV ratio gradient (change per decade)
Table S3. Univariate predictors of baseline left ventricular rel-
ative wall thickness (RWT) and RWT gradient (change per de-
cade)
Table S4. Univariate predictors of baseline left ventricular
end-diastolic volume indexed to body surface area (LVEDVI)
and LVEDVI gradient (change per decade)
Table S5. Univariate predictors of baseline left ventricular
end-systolic volume indexed to body surface area (LVESVI)
and LVESVI gradient (change per decade)
Table S6. Univariate predictors of baseline left ventricular
stroke volume indexed to body surface area (LVSVI) and
LVSVI gradient (change per decade)
Table S7. Univariate predictors of baseline left ventricular
ejection fraction (LVEF) and LVEF gradient (change per de-
cade)
Table S8. Univariate predictors of baseline peak systolic mi-
tral annular velocity (S’) and S’ gradient (change per decade)
Table S9. Univariate predictors of baseline left atrial volume
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indexed to body surface area (LAVI) and LAVI gradient
(change per decade)
Table S10. Univariate predictors of baseline average peak
early diastolic mitral annular velocity (e’) and e’ gradient
(change per decade)
Table S11. Univariate predictors of baseline peak early dia-
stolic mitral velocity to average peak early diastolic mitral an-
nular velocity ratio (E/e’ ratio) and E/e’ ratio gradient (change
per decade)
Table S12. Univariate predictors of baseline tricuspid maxi-
mum regurgitant velocity (TRVmax) and TRVmax gradient
(change per decade)
Table S13.Multivariable predictors of baseline left ventricular
mass indexed to body surface area (LVMI) and LVMI gradient
(change per decade)
Table S14.Multivariable predictors of baseline left ventricular
mass/end-diastolic volume ratio (LVM/EDV ratio) and
LVM/EDV ratio gradient (change per decade)
Table S15.Multivariable predictors of baseline left ventricular
relative wall thickness (RWT) and RWT gradient (change per
decade)
Table S16.Multivariable predictors of baseline left ventricular
end-diastolic volume indexed to body surface area (LVEDVI)
and LVEDVI gradient (change per decade)
Table S17.Multivariable predictors of baseline left ventricular
end-systolic volume indexed to body surface area (LVESVI)
and LVESVI gradient (change per decade)
Table S18.Multivariable predictors of baseline left ventricular
stroke volume indexed to body surface area (LVSVI) and
LVSVI gradient (change per decade)
Table S19.Multivariable predictors of baseline left ventricular
ejection fraction (LVEF) and LVEF gradient (change per
decade)
Table S20. Multivariable predictors of baseline peak systolic
mitral annular velocity (S’) and S’ gradient (change per de-
cade)
Table S21. Multivariable predictors of baseline left atrial vol-
ume indexed to body surface area (LAVI) and LAVI gradient
(change per decade)
Table S22. Multivariable predictors of baseline average peak
early diastolic mitral annular velocity (e’) and e’ gradient
(change per decade)
Table S23. Multivariable predictors of baseline peak early di-
astolic mitral velocity to average peak early diastolic mitral
annular velocity ratio (E/e’ ratio) and E/e’ ratio gradient
(change per decade)
Table S24. Multivariable predictors of baseline tricuspid max-
imum regurgitant velocity (TRVmax) and TRVmax gradient
(change per decade)
Table S25. Multivariable predictors of higher (shown in red)
or lower (shown in blue) baseline echocardiographic parame-
ter values.
Table S26. Multivariable predictors of longitudinal change
(gradient) in echocardiographic parameters per decade of fol-
low-up. Predictors of more rapid increase (or less rapid de-
crease) are shown in red, whereas predictors of more rapid
decrease (or less rapid increase) are shown in blue.
Figure S1. Flow chart of numbers of individuals invited to par-
ticipate in the SCReening Evaluation of the Evolution of New
Heart Failure (SCREEN-HF) study who were subsequently en-
rolled and attended baseline and follow-up echocardio-
graphic examinations.
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